S80040
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱(chēng) 上海源葉生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2024/7/2 20:14:56
- 訪問(wèn)次數(shù) 173
聯(lián)系方式：何小姐15921386130 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息,，謝謝!
生物試劑,ELISA試劑盒,對(duì)照品,標(biāo)準(zhǔn)品,培養(yǎng)基,透析袋,病理科耗材,實(shí)驗(yàn)室耗材
- 提示：詳情請(qǐng)下載說(shuō)明書(shū),。
- 靶點(diǎn)： Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2)
- 體外研究： Apitolisib (GDC-0980) is remarkably selective for several other members of the closely related PIKK family kinases: C2alpha IC50=1300 nM; C2beta IC50=7 94 nM; VPS34 IC50=2000 nM; PI4Kalpha >10 μM; PI4Kbeta >10 μM; DNA-PK Kiapp=623 nM, respectively. A recent study shows that Apitolisib (GDC-0980) reduces cancer cell viability by inhibiting cell-cycle procession and inducing apoptosis with most potency in prostate (IC50 < 200="" nm="" 50%),=""><500 nm="" 100%),="" breast="" (ic50=""><200 nm="" 37%,=""><500 nm="" 78%)="" and="" nsclc="" lines="" (ic50=""><200 nm="" 29%,=""><500 nm="" 88%)="" and="" less="" potency="" in="" pancreatic="" (ic50=""><200 nm="" 13%,=""><500 nm="" 67%)="" and="" melanoma="" cell="" lines="" (ic50=""><200 nm="" 0%,=""><500 nm="" 33%).="">
- 體內(nèi)研究： Apitolisib (GDC-0980) (1 mg/kg, p.o.) demonstrats significant efficacy in mouse xenografts and is currently in phase I clinical trials for cancer. Clearance and PPB are low, and Apitolisib (GDC-0980) shows dose-proportional exposure from 5 mg/kg dosed in PEG to 50 mg/kg dosed in suspension in MCT, a finding attributed partially to the compound’s good solubility. Apitolisib (GDC-0980) (5 mg/kg, p.o.) results in greater than 50% TGI in 15 of the 20 xenograft models. The difference in tumor response to Apitolisib (GDC-0980) treatment correlates with the duration of knockdown of pAkt/tAkt.
- 參考文獻(xiàn)：
[1]. Sutherlin DP, et al. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem, 2011, 54(21), 7579-7587.
[2]. Wallin JJ, et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther, 2011, 10(12), 2426-2436.
- 溶解度： soluble in DMSO
- 保存條件： -20℃
- 配置溶液濃度參考：
1mg 5mg 10mg 1 mM 2.006 ml 10.028 ml 20.056 ml 5 mM 0.401 ml 2.006 ml 4.011 ml 10 mM 0.201 ml 1.003 ml 2.006 ml 50 mM 0.04 ml 0.201 ml 0.401 ml
- 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的性,，僅供客戶參考交流研究之用,。
采購(gòu)中心
化工儀器網(wǎng)